Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Trial details
- Registry ID
- NCT04229979
- Drugs studied
- Azacitidine, Cytarabine, Decitabine, GM-CSF and 4 more
TrialRedline tracks 3 clinical trials sponsored by Sellas Life Sciences Group: 1 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979 | Azacitidine, Cytarabine, Decitabine, GM-CSF and 4 more | Active not recruiting | 2025-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyNCT01265433 | Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF | Completed | 2016-11-30Actual |
| WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)NCT01266083 | GM-CSF, Galinpepimut-S, Montanide | Completed | 2016-09-30Actual |
Names as written in the registry records.